Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18749044 | EMBRYONIC ANGIOGENESIS MARKERS AND DIAGNOSTIC AND THERAPEUTIC STRATEGIES BASED THEREON | June 2024 | October 2025 | Allow | 16 | 2 | 1 | No | No |
| 18648015 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | April 2024 | March 2026 | Abandon | 22 | 1 | 1 | No | No |
| 18636117 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | April 2024 | December 2025 | Allow | 20 | 2 | 1 | No | No |
| 18616600 | METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS | March 2024 | January 2025 | Allow | 10 | 0 | 0 | Yes | No |
| 18610009 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | March 2024 | January 2026 | Abandon | 22 | 0 | 1 | No | No |
| 18589590 | CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME | February 2024 | May 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18590636 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | February 2024 | April 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18587927 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | February 2024 | October 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18440920 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | February 2024 | August 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18544721 | SEMAGLUTIDE DEPOT SYSTEMS AND USE THEREOF | December 2023 | December 2025 | Abandon | 23 | 3 | 1 | Yes | No |
| 18501864 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | November 2023 | June 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18494535 | CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | October 2023 | September 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18483343 | METHOD FOR PROTEIN NANOWIRE SYNTHESIS AND TUNABLE CONTROL OF NANOWIRE LENGTH | October 2023 | April 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18374864 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | September 2023 | April 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18466548 | PEPTIDE COMPOUNDS AND METHODS OF USE | September 2023 | April 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18231483 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | August 2023 | June 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18272674 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | July 2023 | November 2024 | Abandon | 16 | 0 | 1 | Yes | No |
| 18352637 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | July 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18213575 | METHODS OF TREATING LIVER DISEASES COMPRISING AN IBAT INHIBITOR | June 2023 | October 2025 | Abandon | 27 | 3 | 0 | No | No |
| 18204576 | PROTEINOID COMPOUNDS, PROCESS OF PREPARING SAME AND USES THEREOF | June 2023 | February 2026 | Abandon | 33 | 3 | 1 | Yes | No |
| 18322507 | BIOACTIVE PEPTIDES DERIVED FROM SNAKES | May 2023 | March 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18143282 | PEPTIDOMIMETICS AND METHOD OF SYNTHESIS THEREOF | May 2023 | October 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18312100 | METHODS AND COMPOSITION INVOLVING THERMOPHILIC FIBRONECTIN TYPE III (FN3) MONOBODIES | May 2023 | January 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18134277 | CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF | April 2023 | June 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18186724 | FUSION POLYPEPTIDE COMPRISING A FOREIGN ANTIGEN AND SELF ANTIGEN | March 2023 | March 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18177651 | SYSTEMS AND METHODS FOR DELIVERY OF SPADIN FOR TREATMENT OF DEPRESSION OR OTHER INDICATIONS | March 2023 | May 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18172062 | Compositions and Methods for Gene Therapy for Corneal Endothelium Disorders | February 2023 | October 2025 | Abandon | 31 | 2 | 1 | No | Yes |
| 18170914 | SMALL MOLECULE DRUG CONJUGATES | February 2023 | October 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18018364 | PEPTIDE FOR TREATMENT OF CORONA VIRUS INFECTION DISEASE COVID-19 AND USE THEREOF | January 2023 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18158384 | ORTHOGONAL PROTEIN HETERODIMERS | January 2023 | July 2025 | Abandon | 30 | 2 | 1 | No | No |
| 18016660 | Peptide, Peptide Salt, Pharmaceutical Composition and Biological Tissue Calcification Inhibitor | January 2023 | October 2025 | Abandon | 32 | 0 | 1 | No | No |
| 18155457 | METHOD FOR EXTRACTING KERATIN FROM WOOL/NATURAL FIBERS USING IONIC LIQUIDS REINFORCED WITH SONICATION | January 2023 | September 2025 | Allow | 32 | 5 | 1 | Yes | Yes |
| 18154745 | METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE | January 2023 | August 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18067760 | PEPTIDES FOR TREATMENT AND PREVENTION OF NONALCOHOLIC FATTY LIVER DISEASE AND FIBROSIS | December 2022 | July 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 18001913 | IL-10 MUTEINS AND FUSION PROTEINS THEREOF | December 2022 | November 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 18078475 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS | December 2022 | March 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18063494 | COMPOSITIONS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASE | December 2022 | April 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18057110 | Pharmaceutical composition including laminin fragments to treat or prevent the disease, disorder or symptom of tooth dentin and/or dental pulp | November 2022 | April 2024 | Allow | 17 | 1 | 0 | No | No |
| 18053981 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | November 2022 | February 2024 | Allow | 15 | 0 | 1 | Yes | No |
| 17977778 | TARGETED PHARMACOLOGICAL THERAPEUTICS IN UVEAL MELANOMA | October 2022 | October 2024 | Abandon | 24 | 2 | 1 | No | No |
| 18049917 | REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS | October 2022 | July 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18047779 | METABOLICALLY STABLE PEPTIDE ANALOGS | October 2022 | May 2024 | Abandon | 19 | 1 | 1 | No | No |
| 17917420 | SOLUBLE ACE2 FOR TREATMENT OF COVID-19 | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17935177 | TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF | September 2022 | November 2023 | Allow | 14 | 1 | 1 | No | No |
| 17946380 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | September 2022 | April 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17929980 | TOPICAL PHARMACEUTICAL FORMULATIONS OF A CYCLIC DEPSIPEPTIDE | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17905747 | PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | September 2022 | March 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17901520 | CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | September 2022 | July 2023 | Allow | 11 | 0 | 0 | Yes | No |
| 17889754 | COLLAGEN HYDROLYSATE AS ACTIVE SUBSTANCE AGAINST PERIODONTITIS OR GINGIVITIS | August 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17885368 | SAFE DESMOPRESSIN ADMINISTRATION | August 2022 | May 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17817252 | PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME | August 2022 | June 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17812934 | ANTI-TUMOR POLYPEPTIDE Bax-BH3, FLUORESCENT POLYMERIC NANOMICELLE, PREPARATION METHOD AND USE THEREOF | July 2022 | February 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 17859490 | METHODS FOR TREATING CANCERS USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS | July 2022 | January 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17788264 | METHOD FOR PRODUCING PEPTIDE | June 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17807209 | MODIFIED ANTIMICROBIAL PEPTIDES | June 2022 | June 2025 | Allow | 36 | 3 | 1 | Yes | No |
| 17837360 | COMPOUNDS AND METHODS FOR SELECTIVE C-TERMINAL LABELING | June 2022 | June 2025 | Abandon | 36 | 2 | 1 | Yes | Yes |
| 17782200 | Etelcalcetide intermediate and method for synthesizing etelcalcetide | June 2022 | December 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17826623 | METHODS AND COMPOSITIONS FOR MENISCAL REPAIR USING BIOADHESIVE PROTEINS | May 2022 | December 2024 | Abandon | 30 | 1 | 1 | Yes | No |
| 17745104 | PROTEIN HYDROLYSATES | May 2022 | December 2024 | Abandon | 31 | 4 | 1 | No | No |
| 17743835 | HEME SEQUESTING PEPTIDES AND USES THEREFOR | May 2022 | August 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17773734 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | May 2022 | March 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17712706 | METHODS AND COMPOSITIONS FOR VISUALIZING SUMO | April 2022 | January 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17766250 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | April 2022 | December 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17765976 | ANTIMICROBIAL PEPTIDES | April 2022 | July 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17764184 | COMPOSITION AND APPLICATION THEREOF IN PREPARATION OF SKIN CARE PRODUCTS FOR REGULATING SKIN BIORHYTHM | March 2022 | January 2026 | Abandon | 46 | 2 | 1 | No | No |
| 17700120 | MODIFIED COLLAGEN | March 2022 | May 2025 | Abandon | 37 | 2 | 1 | No | Yes |
| 17642936 | INHIBITING ZD17-JNK INTERACTION AS A THERAPY FOR ACUTE MYOCARDIAL INFARCTION | March 2022 | February 2026 | Abandon | 47 | 2 | 1 | No | No |
| 17642082 | SKIN LIGHTENING COMPOSITION | March 2022 | March 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17654060 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE | March 2022 | May 2025 | Abandon | 38 | 4 | 1 | Yes | No |
| 17680778 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | February 2022 | November 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17679925 | KV1.3 BLOCKERS | February 2022 | May 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17650792 | NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES | February 2022 | May 2024 | Abandon | 28 | 1 | 1 | Yes | No |
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | February 2022 | November 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17588579 | Crystal Structures Comprising Elastin-Like Peptides | January 2022 | February 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17579408 | COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR CANCER TREATMENT AND METABOLIC INTERVENTION THERAPY AND OTHER USES | January 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17573304 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | January 2022 | February 2026 | Abandon | 49 | 0 | 1 | No | No |
| 17572524 | CHIMERIC LYSM POYLPEPTIDES | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17571283 | PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF | January 2022 | October 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17625131 | Fusion Protein And Composition For Treating Animal Tumors | January 2022 | July 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17569402 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | January 2022 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17567667 | COMPOSITIONS AND METHODS FOR DISASSEMBLING AMYLOID FIBRILS | January 2022 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17624487 | Functionalized Nanoparticles and Their Use in Treating Bacterial Infections | January 2022 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17561342 | MONOFUNCTIONAL BRANCHED POLYETHYLENE GLYCOL AND MODIFIED BIO-RELATED SUBSTANCE THEREOF | December 2021 | November 2025 | Abandon | 46 | 6 | 1 | Yes | No |
| 17621385 | THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE | December 2021 | November 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17620368 | PEPTIDE NUCLEIC ACID COMPOSITIONS WITH MODIFIED HOOGSTEEN BINDING SEGMENTS AND METHODS OF USE THEREOF | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17553008 | DOSING REGIMEN | December 2021 | October 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17552087 | Cyclic Peptide Antiviral Agents and Methods Using Same | December 2021 | May 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17617730 | SUPRAMOLECULAR STRUCTURES | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17617675 | PHARMACEUTICAL PARENTERAL COMPOSITION OF DUAL GLP1/2 AGONIST | December 2021 | October 2025 | Abandon | 46 | 2 | 1 | Yes | No |
| 17542473 | Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof | December 2021 | August 2024 | Allow | 32 | 0 | 1 | No | No |
| 17541636 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | December 2021 | March 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17535527 | ANTIBACTERIAL COMPOSITION EFFECTIVE IN TREATING GRAM NEGATIVE BACTERIAL INFECTIONS AND METHOD FOR PREPARING THE SAME | November 2021 | November 2022 | Allow | 12 | 0 | 1 | Yes | No |
| 17534427 | PH-Responsive Nanoparticles for Treating Cancer | November 2021 | September 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17613527 | PIC1 PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17532307 | Peptide Compounds and Methods of Use in Wound Healing | November 2021 | June 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17529534 | Coversin Variants Lacking C5 Binding | November 2021 | June 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17528144 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | November 2021 | January 2025 | Allow | 38 | 4 | 1 | Yes | No |
| 17454665 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) | November 2021 | December 2023 | Allow | 25 | 2 | 1 | Yes | No |
| 17595224 | NOVEL THERAPEUTIC AGENT FOR GASTROINTESTINAL CANCER AND METHOD FOR SCREENING FOR THE SAME | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17518074 | CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF | November 2021 | January 2023 | Allow | 14 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner REYNOLDS, FRED H.
With a 42.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner REYNOLDS, FRED H works in Art Unit 1658 and has examined 359 patent applications in our dataset. With an allowance rate of 36.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner REYNOLDS, FRED H's allowance rate of 36.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by REYNOLDS, FRED H receive 2.50 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by REYNOLDS, FRED H is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by REYNOLDS, FRED H. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 8.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.3% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 76.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 61% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 56.8% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 56.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 95.1% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.